Daniel A Laheru

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct
    Michael A Hughes
    Therapeutic Radiologists, Inc, Kansas City, MO, USA
    Int J Radiat Oncol Biol Phys 68:178-82. 2007
  2. doi request reprint Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine
    Dan Laheru
    The Sidney Kimmel Cancer Center, the Skip Viragh Clinical Pancreatic Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Methods Mol Biol 980:175-203. 2013
  3. pmc Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer
    Daniel Laheru
    Department of Medical Oncology, Skip Viragh Center for Pancreatic Cancer Research and Patient Care, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Room 4M09, Baltimore, MD 21231, USA
    Invest New Drugs 30:2391-9. 2012
  4. pmc Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study
    Amol K Narang
    Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Radiat Oncol 6:126. 2011
  5. pmc Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation
    Dan Laheru
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Public Health, Baltimore, Maryland 21231, USA
    Clin Cancer Res 14:1455-63. 2008
  6. pmc A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer
    Dan Laheru
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 14:5602-9. 2008
  7. pmc Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas
    Michael J Swartz
    Department of Radiation Oncology and Molecular Radiation Sciences, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Hospital, Baltimore, MD 21231 2410, USA
    Int J Radiat Oncol Biol Phys 76:839-44. 2010
  8. doi request reprint Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Int J Radiat Oncol Biol Phys 86:678-85. 2013
  9. pmc Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study
    Charles C Hsu
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Hospital, Baltimore, MD, USA
    Ann Surg Oncol 17:981-90. 2010
  10. pmc Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
    Dung T Le
    The Sidney Kimmel Cancer Center, the Skip Viragh Center for Pancreatic Cancer, Research and Clinical Care, and the Sol Goldman Pancreatic Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Immunother 36:382-9. 2013

Research Grants

Detail Information

Publications30

  1. ncbi request reprint Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct
    Michael A Hughes
    Therapeutic Radiologists, Inc, Kansas City, MO, USA
    Int J Radiat Oncol Biol Phys 68:178-82. 2007
    ..To examine the effect of adjuvant chemoradiation for adenocarcinoma of the distal common bile duct (DCBD) after pancreaticoduodenectomy (PD) on local control and survival...
  2. doi request reprint Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine
    Dan Laheru
    The Sidney Kimmel Cancer Center, the Skip Viragh Clinical Pancreatic Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Methods Mol Biol 980:175-203. 2013
    ..Without knowledge of specific antigen targets, the whole tumor cell represents the best source of immunizing antigens. This chapter will focus on the development of whole tumor cell vaccine strategies for pancreas cancer...
  3. pmc Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer
    Daniel Laheru
    Department of Medical Oncology, Skip Viragh Center for Pancreatic Cancer Research and Patient Care, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Room 4M09, Baltimore, MD 21231, USA
    Invest New Drugs 30:2391-9. 2012
    ..This study evaluated the activity, safety, and toxicity of salirasib in preclinical models and patients with metastatic pancreatic adenocarcinoma (PDA)...
  4. pmc Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study
    Amol K Narang
    Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Radiat Oncol 6:126. 2011
    ..We combined the experience of two institutions to better delineate which patients may benefit from adjuvant chemoradiation...
  5. pmc Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation
    Dan Laheru
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Public Health, Baltimore, Maryland 21231, USA
    Clin Cancer Res 14:1455-63. 2008
    ....
  6. pmc A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer
    Dan Laheru
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 14:5602-9. 2008
    ....
  7. pmc Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas
    Michael J Swartz
    Department of Radiation Oncology and Molecular Radiation Sciences, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Hospital, Baltimore, MD 21231 2410, USA
    Int J Radiat Oncol Biol Phys 76:839-44. 2010
    ..Intraductal papillary mucinous neoplasms are mucin-producing cystic neoplasms of the pancreas. One-third are associated with invasive carcinoma. We examined the benefit of adjuvant chemoradiotherapy (CRT) for this cohort...
  8. doi request reprint Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Int J Radiat Oncol Biol Phys 86:678-85. 2013
    ..Gemcitabine-erlotinib therapy has demonstrated a survival benefit for patients with metastatic PDAC. Here we report the first phase 2 study of erlotinib in combination with adjuvant chemoradiation and chemotherapy for resected PDAC...
  9. pmc Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study
    Charles C Hsu
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Hospital, Baltimore, MD, USA
    Ann Surg Oncol 17:981-90. 2010
    ..Our goal was to examine efficacy of adjuvant CRT in resected pancreatic adenocarcinoma compared with surgery alone...
  10. pmc Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
    Dung T Le
    The Sidney Kimmel Cancer Center, the Skip Viragh Center for Pancreatic Cancer, Research and Clinical Care, and the Sol Goldman Pancreatic Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Immunother 36:382-9. 2013
    ..014) and enhancement of the T-cell repertoire (P = 0.031). In conclusion, checkpoint blockade in combination with GVAX has the potential for clinical benefit and should be evaluated in a larger study...
  11. doi request reprint Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, 401 N Broadway, Weinberg Suite 1440, Baltimore, MD 21231, USA
    J Clin Oncol 31:886-94. 2013
    ..We herein report final results of the largest randomized phase III trial performed to date among patients with locally advanced pancreatic cancer (LAPC) and the first to test gene transfer against this malignancy...
  12. pmc Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer
    Charles C Hsu
    The Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 410 North Broadway Suite 1440, Baltimore, MD 21231 2410, USA
    J Gastrointest Surg 16:753-61. 2012
    ..This study examines the preoperative predictors of early mortality following PD and combines these variables into an early mortality risk score (EMRS)...
  13. doi request reprint Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: a new approach to adjuvant radiation field design
    Avani S Dholakia
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    Int J Radiat Oncol Biol Phys 87:1007-15. 2013
    ....
  14. pmc Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making
    Hari Nathan
    Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 19:3668-76. 2012
    ..Criteria for resectability of colon cancer liver metastases (CLM) are evolving, yet little is known about how physicians choose a therapeutic strategy for potentially resectable CLM...
  15. pmc Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer
    Nilofer Azad
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Bldg, Room 1M52, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Invest New Drugs 31:345-54. 2013
    ..v. days 1, 8; cetuximab 400 mg/m(2) i.v. days 1 and 250 mg/m(2) i.v. weekly; and sorafenib 400 mg orally twice daily in advanced, pretreated CRC. The combination resulted in a modest response rate...
  16. pmc Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Hospital, Baltimore, MD, USA
    J Clin Oncol 26:3503-10. 2008
    ..To examine the efficacy of adjuvant chemoradiotherapy after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PC) in patients undergoing resection at Johns Hopkins Hospital (JHH; Baltimore, MD)...
  17. pmc Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival
    George J Arnaoutakis
    Division of Thoracic Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Gastrointest Surg 15:1611-7. 2011
    ..This study was conducted to determine if pulmonary metastasectomy (PM) for isolated pancreatic cancer metastases is safe and effective...
  18. ncbi request reprint Baseline hemoglobin-a1c impacts clinical outcomes in patients with pancreatic cancer
    Katherine Y Fan
    From the aDepartment of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland bDepartment of Statistics, Stanford University, Palo Alto, California cDepartment of Radiation Oncology, University of California San Francisco, San Francisco, California and dDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, eDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, fRussell H Morgan Department of Radiology and Radiological Sciences, gDivision of Endocrinology and Metabolism, Department of Internal Medicine, and hDepartment of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    J Natl Compr Canc Netw 12:50-7. 2014
    ..5% or greater influence OS of patients with PDA even when accounting for other known prognostic factors. HbA1c level at presentation is significantly higher in patients with PDA than patients with BPD and seems to affect survival. ..
  19. pmc A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction
    Dung T Le
    The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 18:858-68. 2012
    ..These two phase I studies test ANZ-100 and CRS-207 in subjects with liver metastases and mesothelin-expressing cancers, respectively...
  20. doi request reprint Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning
    Haoming Qiu
    Department of Radiation Oncology and Molecular Radiation Sciences, Sol Goldman Pancreatic Cancer Research Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Radiother Oncol 104:167-72. 2012
    ....
  21. pmc Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors
    Antonio Jimeno
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Cancer Research Building I, Baltimore, MD, USA
    Cancer Chemother Pharmacol 61:423-33. 2008
    ....
  22. pmc Recent progress in pancreatic cancer
    Christopher L Wolfgang
    Associate Professor, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD Associate Professor, Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD Associate Professor, Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD
    CA Cancer J Clin 63:318-48. 2013
    ..It is clear that multidisciplinary care that provides comprehensive and coordinated evaluation and treatment is the most effective way to manage patients with pancreatic cancer...
  23. doi request reprint Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine
    Aaron J Schueneman
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 20:S725-30. 2013
    ..Although immune-based therapies are under rapid development, it is not known whether baseline complete blood counts, particularly lymphocytes, are associated with the clinical outcomes of patients receiving immunotherapies...
  24. pmc Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors
    Shinichi Yachida
    Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Clin Cancer Res 18:6339-47. 2012
    ..Genetic alterations of KRAS, CDKN2A, TP53, and SMAD4 are the most frequent events in pancreatic cancer. We determined the extent to which these 4 alterations are coexistent in the same carcinoma, and their impact on patient outcome...
  25. ncbi request reprint Role of adjuvant therapy in the management of pancreatic cancer
    Dan Laheru
    Department of Medical Oncology, The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Adv Surg 39:223-44. 2005
  26. ncbi request reprint Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum
    Michael J Swartz
    Department of Radiation Oncology and Molecular Radiation Sciences, Baltimore, MD 21231, USA
    Arch Surg 142:285-8. 2007
    ..Adjuvant chemoradiation improves local control and survival in patients with node-positive duodenal adenocarcinoma treated with pancreaticoduodenectomy...
  27. pmc Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients
    Amy Morck Thomas
    Department of Oncology, The Sidney Kimmel Cancer Center at Johns Hopkins, The Bunting Blaustein Cancer Research Bldg, Rm 4M07, 1650 Orleans St, Baltimore, MD 21231, USA
    J Exp Med 200:297-306. 2004
    ..These results provide the first direct evidence that CD8 T cell responses can be generated via cross-presentation by an immunotherapy approach designed to recruit APCs to the vaccination site...
  28. ncbi request reprint Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities
    Wells A Messersmith
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Clin Cancer Res 10:6522-7. 2004
    ....
  29. ncbi request reprint Immunotherapy for pancreatic cancer - science driving clinical progress
    Dan Laheru
    Department of Medical Oncology, Room G89, Baltimore, Maryland 21231 1000, USA
    Nat Rev Cancer 5:459-67. 2005
    ..Immunotherapy for pancreatic cancer is one approach that is at a crucial crossroads, as therapeutics that are designed to target pancreatic-cancer-associated antigens and regulatory signalling molecules are entering clinical trials...
  30. ncbi request reprint Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine
    Dan Laheru
    The Sidney Kimmel Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Methods Mol Med 103:299-327. 2005
    ..Without knowledge of specific antigen targets, the whole tumor cell represents the best source of immunizing antigens. This chapter will focus on the development of whole tumor cell vaccine strategies for pancreas cancer...

Research Grants2

  1. Gene Modified Cell Lines as Vaccine for Pancreas Cancer
    Daniel Laheru; Fiscal Year: 2006
    ..Finally, these data will provide valuable information on how to best integrate the vaccine with other therapeutic modalities including surgery, radiotherapy and chemotherapy. ..